Objective To explore the
efficacy and
safety of daclatasvir (DCV ) combined with asunprevir (ASV) for chronic
genotype 1b (GT1b)
hepatitis C .
Methods Twenty-nine GT1b
hepatitis C patients who were treated with DCV combined ASV in Henan Provincial People′s
Hospital from September 2017 to November 2017 were included .
Hepatitis C virus (HCV )
RNA levels were tested before
treatment ,1 week ,2 weeks ,3 weeks ,4 weeks ,8 weeks ,12 weeks and 24 weeks
after treatment , and 12 weeks after the end of the
treatment .The comorbidities ,combined use of
drugs and adverse clinical events were registered .T test was used to compare the measurement data with
normal distribution and M (P25,P75) was used for measurement data with non-
normal distribution .Results A total of 29
patients with GT1b were included ,with 4
cirrhosis cases and 25 non cirrhotic cases .Seven
patients had
history of previous
interferon and
ribavirin combination
treatment .There were 9
patients with
comorbidity and 7
patients with combined medication . Finally , 25
patients completed a 24-week
course of
antiviral treatment ;3
patients were
lost to follow-up ,and 1
patient withdrew after 16weeks of
antiviral treatment because of a
virus rebound .Of the 26 followed up
patients ,25 achieved sustained virological response at 12-week (SVR12 ) , and one
patient failed .And the HCV
RNA NS5A resistance-associated variants (RAV) were detected in the
patients with
treatment failure .No severe adverse clinical events occurred in 26
patients .Conclusions DCV combined with ASV is effective and safe in the
treatment of GT 1b
chronic hepatitis C .However , the effect of RAV on
therapeutic efficacy should be concerned during the
treatment .